Free Trial

Avid Bioservices (CDMO) Stock Price, News & Analysis

+0.01 (+0.11%)
(As of 11:04 AM ET)
Today's Range
50-Day Range
52-Week Range
37,347 shs
Average Volume
1.25 million shs
Market Capitalization
$577.03 million
P/E Ratio
Dividend Yield
Price Target

Avid Bioservices MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
59.5% Upside
$14.50 Price Target
Short Interest
17.42% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.72mentions of Avid Bioservices in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$127,546 Sold Last Quarter
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

246th out of 922 stocks

Pharmaceutical Preparations Industry

95th out of 413 stocks

CDMO stock logo

About Avid Bioservices Stock (NASDAQ:CDMO)

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

CDMO Stock Price History

CDMO Stock News Headlines

Avid Bioservices (NASDAQ:CDMO) Shares Up 4%
Q3 2024 Avid Bioservices Inc Earnings Call
CDMO Dec 2024 10.000 call
CDMO Apr 2024 15.000 call
CDMO Dec 2024 2.500 call
Why Is Avid Bioservices (CDMO) Stock Down 30% Today?
See More Headlines
Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$149.27 million
Cash Flow
$0.15 per share
Book Value
$3.02 per share


Free Float
Market Cap
$577.03 million
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

CDMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CDMO shares.
View CDMO analyst ratings
or view top-rated stocks.

What is Avid Bioservices' stock price target for 2024?

4 Wall Street research analysts have issued 1 year target prices for Avid Bioservices' stock. Their CDMO share price targets range from $8.00 to $20.00. On average, they anticipate the company's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 59.5% from the stock's current price.
View analysts price targets for CDMO
or view top-rated stocks among Wall Street analysts.

How have CDMO shares performed in 2024?

Avid Bioservices' stock was trading at $6.50 at the beginning of the year. Since then, CDMO shares have increased by 39.8% and is now trading at $9.09.
View the best growth stocks for 2024 here

When is Avid Bioservices' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 19th 2024.
View our CDMO earnings forecast

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) released its quarterly earnings results on Wednesday, April, 24th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.06. The biopharmaceutical company had revenue of $33.82 million for the quarter, compared to analyst estimates of $33.80 million. Avid Bioservices had a negative net margin of 13.10% and a negative trailing twelve-month return on equity of 8.78%.

What ETF holds Avid Bioservices' stock?

Franklin Genomic Advancements ETF holds 7,643 shares of CDMO stock, representing 0.69% of its portfolio.

When did Avid Bioservices' stock split?

Avid Bioservices shares reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices issued an update on its FY 2024 earnings guidance on Wednesday, April, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $137.0 million-$147.0 million, compared to the consensus revenue estimate of $138.7 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.77%), 12 West Capital Management LP (4.33%), AWM Investment Company Inc. (1.09%), Kennedy Capital Management LLC (0.94%), Rice Hall James & Associates LLC (0.62%) and BNP Paribas Financial Markets (0.49%). Insiders that own company stock include Daniel R Hart, Gregory Sargen, Joseph Carleone, Mark R Ziebell, Matthew R Kwietniak, Nicholas Stewart Green, Richard A Richieri and Richard B Hancock.
View institutional ownership trends

How do I buy shares of Avid Bioservices?

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDMO) was last updated on 5/22/2024 by Staff

From Our Partners